ArticleBiologics : targets & therapy2026

Real-World Outcomes of a Non-Medical Switch to Adalimumab-Atto Biosimilar: Safety, Effectiveness, and Treatment Persistence in an Adult Saudi Tertiary Care Population.

Alhanouf Almousa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.